An experimental drug called daraxonrasib nearly doubled the median overall survival rate for patients with metastatic pancreatic cancer in a late-stage trial.
This development targets one of the most lethal forms of cancer by inhibiting a specific mutation that was long considered impossible to treat. Because pancreatic cancer often progresses rapidly, any significant extension of life represents a major shift in clinical outcomes.
Results from the study were presented this week at the American Society of Clinical Oncology (ASCO) 2026 meeting in Chicago. The drug targets the KRAS mutation, which drives the majority of pancreatic tumors [1]. By inhibiting this protein, daraxonrasib prevents the signaling that allows cancer cells to grow and spread [2].
According to data from the trial, patients receiving the experimental drug saw a median overall survival of 13.2 months [3]. In comparison, patients in the control group receiving standard chemotherapy had a median overall survival of 6.7 months [3]. This gap represents a relative risk reduction of death by 60% [4].
There are conflicting reports regarding the scale of the research. One report identifies the study as a phase 3 trial involving 500 patients [3]. Another report describes the research as a first-in-human trial with 168 patients [5].
Despite the discrepancy in trial size, the clinical data suggests a breakthrough in treating metastatic disease. The drug's ability to target the KRAS mutation provides a new pathway for treatment in a patient population with very few effective options.
“Median overall survival in the experimental arm reached 13.2 months.”
The success of daraxonrasib marks a pivotal transition in oncology by proving that the KRAS mutation—historically labeled as 'undruggable'—can be effectively targeted. While the survival increase from 6.7 to 13.2 months does not constitute a cure, it provides a significant clinical window for patients with metastatic disease and may pave the way for combination therapies that further extend life expectancy.
